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Objective. Generalized DNA hypomethylation
contributes to altered T cell function and gene expres-
sion in systemic lupus erythematosus (SLE). Some of
the overexpressed genes participate in the disease pro-
cess, but the full repertoire of genes affected is un-
known. Methylation-sensitive T cell genes were identi-
fied by treating T cells with the DNA methyltransferase
inhibitor 5-azacytidine and comparing gene expression
with oligonucleotide arrays. CD70, a costimulatory li-
gand for B cell CD27, was one gene that reproducibly
increased. We then determined whether CD70 is over-
expressed on T cells treated with other DNA methyl-
ation inhibitors and on SLE T cells, and determined its
functional significance.
Methods. Oligonucleotide arrays, real-time re-
verse transcription–polymerase chain reaction, and flow
cytometry were used to compare CD70 expression in T
cells treated with 2 DNA methyltransferase inhibitors
(5-azacytidine and procainamide) and 3 ERK pathway
inhibitors known to decrease DNA methyltransferase
expression (U0126, PD98059, and hydralazine). The
consequences of CD70 overexpression were tested by
coculture of autologous T and B cells with and without
anti-CD70 and measuring IgG production by enzyme-
linked immunosorbent assay. The results were com-
pared with those of T cells from lupus patients.
Results. SLE T cells and T cells treated with DNA
methylation inhibitors overexpressed CD70 and over-
stimulated B cell IgG production. The increase in IgG
synthesis was abrogated by anti-CD70.
Conclusion. SLE T cells and T cells treated with
DNA methyltransferase inhibitors and ERK pathway
inhibitors overexpress CD70. This increased B cell
costimulation and subsequent immunoglobulin over-
production may contribute to drug-induced and idio-
pathic lupus.
CD4 T cell DNA hypomethylation may contrib-
ute to the development of drug-induced and idiopathic
systemic lupus erythematosus (SLE). DNA methylation
refers to the methylation of deoxycytosine (dC) bases in
CG pairs, and it is one of the mechanisms by which gene
expression is suppressed (1). CD4 T cells treated in
vitro with the DNA methylation inhibitors 5-azacytidine
(5-azaC), procainamide, or hydralazine became autore-
active, killing autologous or syngeneic macrophages and
promoting antibody production (2–5). Adoptive transfer
of the autoreactive cells caused a lupus-like disease
(4,5). The autoreactivity was found to be due in part to
an overexpression of the adhesion molecule lymphocyte
function–associated antigen 1 (LFA-1; CD11a/CD18)
(6,7), and abnormal perforin expression contributed to
the macrophage killing (8,9). The mechanisms by which
the demethylated T cells promote antibody synthesis are
not completely understood.
The genomic deoxymethylcytosine (dmC) content
was also shown to be decreased in T cells from patients
with active SLE, similar to that in T cells treated with
5-azaC, procainamide, and hydralazine (10). LFA-1 was
also shown to be overexpressed on a CD4, perforin-
expressing, cytotoxic, autoreactive lupus T cell subset
with major histocompatibility complex specificity identi-
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cal to that of T cells treated with DNA methylation
inhibitors (8,11). Furthermore, the same LFA-1 and
perforin regulatory sequences were shown to be demeth-
ylated in CD4 T cells from patients with active SLE as
in T cells treated with 5-azaC or procainamide (8,12).
Together, these studies suggest that T cell DNA hypo-
methylation may be fundamental to the pathogenesis of
autoimmunity in the adoptive transfer model (4,5) and
in humans with drug-induced and idiopathic lupus.
While overexpression of LFA-1 and, perhaps, perforin is
important to the disease process in the DNA hypo-
methylation model (7,13) and possibly in human lupus
(8,11,14), the repertoire of genes that are affected is
unknown, and other genes may also contribute to dis-
ease pathogenesis through mechanisms that promote
antibody synthesis.
We identified additional methylation-sensitive
genes by treating phytohemagglutinin (PHA)–
stimulated human T lymphocytes with 5-azaC, then
analyzing gene expression using oligonucleotide arrays.
One gene that reproducibly increased 2-fold was
CD70, which is also known as CD27 ligand (CD27L).
CD70 is a member of the tumor necrosis factor (TNF)
family that is expressed on activated CD4 and CD8
T cells and B cells (15). Adding cells transfected with
CD70 was shown to increase pokeweed mitogen
(PWM)–stimulated IgG synthesis in T cell–dependent B
cell assays (16), indicating that CD70 has B cell–
costimulatory functions resembling those of CD40L
(16). This suggests that T cells overexpressing CD70 as a
result of either DNA methylation inhibitor treatment or
the DNA hypomethylation associated with lupus may
also provide additional B cell–costimulatory signals.
In these studies, we sought to determine whether
CD70 expression is increased on T cells treated with a
panel of DNA methylation inhibitors and, if so, whether
the hypomethylated T cells overexpressing CD70 could
overstimulate the production of IgG by B cells. The
DNA methylation inhibitors we used included the direct
DNA methyltransferase inhibitors 5-azaC and procain-
amide (17), as well as PD98059, U0126, and hydralazine,
which decrease DNA methyltransferase expression by
inhibiting ERK pathway signaling (18). It is likely that
ERK pathway inhibition is more relevant to idiopathic
SLE in humans than is direct DNA methyltransferase
inhibition, because T cells from patients with active
lupus have impaired ERK pathway signaling, associated
with decreased DNA methyltransferase levels and hy-
pomethylated DNA (19). Similar studies were then
performed on T cells from SLE patients. The results
suggest that CD70 overexpression may contribute to B
cell IgG overproduction induced by experimentally hy-
pomethylated T cells and by T cells from patients with
idiopathic SLE.
MATERIALS AND METHODS
Subjects. SLE patients (n  14) were recruited from
the outpatient and inpatient services at the University of
Michigan. Age-, race-, and sex-matched control subjects (n 
17) were recruited by advertising. The study protocol was
approved by the University of Michigan Institutional Review
Board. Patients with SLE met 4 criteria for the classification of
lupus (20), and disease activity was assessed using the SLE
Disease Activity Index (SLEDAI) (21). Active disease was
defined as a SLEDAI score 5. Relevant clinical information
regarding the study subjects is shown in Table 1.
Cells and cell culture. Peripheral blood mononuclear
cells (PBMCs) were isolated by density-gradient centrifuga-
tion. T cells were then isolated by E-rosetting, as previously
described (22). Purity, assessed by staining with fluorescein
isothiocyanate (FITC)–conjugated anti-CD3 and flow cytom-
etry, was typically 87–94%. Where indicated, the cells were
cultured in RPMI 1640/10% fetal calf serum (FCS) supple-
mented with interleukin-2 (IL-2), as described previously (3),
in round-bottomed 5-ml culture tubes (Falcon, Franklin Lakes,
NJ). Cells were stimulated with 1 g/ml of PHA (Remel,
Lenexa, KS) for 16 hours, then cultured in 24-well plates at a
density of 1  106 for an additional 72 hours in the presence of
2-deoxy-5-azaC or 5-azaC (Aldrich, St. Louis, MO), procain-
amide (Aldrich), hydralazine (Aldrich), or the MEK inhibitors
U0126 (Promega, Madison, WI) or PD98059 (Promega).
In other studies, PHA-stimulated PBMCs were cul-
tured in RPMI 1640/10% FCS and treated with indomethacin,
chloroquine, hydrocortisone, and 6-mercaptopurine (6-MP),
all from Sigma (St. Louis, MO). TT48E, a cloned, CD4,
tetanus toxoid–reactive human T cell line, was cultured as
previously described (2,11).
Oligonucleotide array analysis. Messenger RNA
(mRNA) was isolated from untreated or 2-deoxy-5-azaC–
treated T cells, and analyzed using Affymetrix U95A oligo-
nucleotide arrays, as previously described (9).
Real-time reverse transcription–polymerase chain re-
action (RT-PCR). CD70 transcripts were quantitated by real-
time RT-PCR using a LightCycler (Roche, Indianapolis, IN)
and previously published protocols (9). The following primers
were used: forward, 5-TGCTTTGGTCCCATTGGTCG-3
and reverse, 5-TCCTGCTGAGGTCCTGTGTGATTC-3.
The transcripts were measured relative to -actin as described
previously (9).
Flow cytometric analysis. The following fluorochrome-
conjugated monoclonal antibodies were obtained from BD
PharMingen (San Diego, CA): FITC-conjugated anti-human
CD70, CD2, or isotype-matched controls; phycoerythrin (PE)–
conjugated anti-CD2, CD4, and CD8; and CyChrome-
conjugated anti–HLA–DR, CD2, and isotype controls. Stain-
ing and multicolor flow cytometric analysis were performed as
previously described (23), using saturating concentrations of
antibody.
T cell and B cell costimulation assays. E-rosette–
purified T cells were stimulated for 16 hours with PHA and
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then treated with the indicated chemicals for an additional 72
hours as described above. Where indicated, T cell subsets were
isolated by negative selection using magnetic beads (Miltenyi
Biotec, Sunnyvale, CA). B cells (1–4  105) enriched by
negative selection using magnetic beads (Miltenyi Biotec) and
assessed to be 70–85% pure using PE-conjugated anti-human
CD21 (PharMingen), were added to washed, drug-treated
autologous T cells, at T cell to B cell ratios of 4:1, 2:1, 1:1, 1:2,
and 1:4. Where indicated, 0.625 g/ml of PWM (Aldrich) was
added. The cells were cultured in RPMI 1640/10% FBS/
penicillin/streptomycin for 8 days in 96-well round-bottomed
plates (Costar, Corning NY) containing a 200-l total volume
(performed in duplicate). Cells were supplemented with 50 l
of medium on day 4. Where indicated, 1 g/ml of anti-CD70
monoclonal antibody (HNE51; Dako, Glostrup, Denmark)
was added to the cultures.
TT48E cells were similarly stimulated with PHA (1
g/ml) for 18 hours, treated with the indicated drugs for 3 days,
then similarly cultured with autologous B cells for 8 days.
Where indicated, the TT48E cells were pretreated with 1
g/ml of anti-CD70 for 30 minutes at 4°C, then washed and
added to the B cells, according to protocols described by others
(16).
CD4 T cells were similarly isolated from lupus
patients by first purifying the T cells by E-rosetting, then
depleting the CD8 T cells using magnetic beads (Miltenyi
Biotec). These cells were then similarly cultured with purified
autologous B cells. Where indicated, the T cells were pre-
treated with anti-CD70.
IgG enzyme-linked immunosorbent assays (ELISAs).
IgG was measured in the supernatants of the T cell–B cell
cultures as previously described (3). Briefly, 96-well flat-
bottomed polystyrene plates (Costar) were coated with 1 g/ml
of goat anti-human IgG (Southern Biotech, Birmingham AL)
and washed. Unreacted combining sites were sealed with 3%
bovine serum albumin (BSA) in phosphate buffered saline
(PBS) by incubation at 4°C for 16 hours. Pooled supernatants
from duplicate wells were diluted 1:5 in PBS/1% BSA, and 50
l was added to the wells. Serial dilutions of purified human
IgG (Sigma) were used for quantitation. Following incubation
and washing, goat anti-human IgG conjugated with horserad-
ish peroxidase (Southern Biotech) was added, and cells were
incubated for 2 hours at room temperature. The wells were
washed 3 times with PBS/0.1% Tween 20, and color was
developed using Sigma Fast tablets. The plates were read at
405 nm using a SpectraMax spectrophotometer (Molecular
Devices, Sunnyvale, CA). All determinations were performed
in quadruplicate.
Statistical analysis. The difference between means was
tested by Student’s unpaired t-test. Power, regression analyses,
and analysis of variance were performed using Systat 10
software (Richmond, CA).
RESULTS
Identification of methylation-sensitive T cell
genes. In preliminary studies, we used oligonucleotide
arrays to identify T cell genes affected by DNA methyl-
ation inhibition. Purified T cells were stimulated with
PHA and treated with 2-deoxy-5-azaC as described in
Materials and Methods. Three days later, gene expres-
sion was compared in treated and untreated cells using
oligonucleotide arrays. Overall, 118 genes reproducibly
increased 2-fold, and 12 genes decreased 2-fold. In 2
independent experiments, CD70 expression increased
2.6  0.6–fold (mean  SEM) in treated cells relative to
untreated controls (Figure 1A). These results were





1 49/W/F 6 HCQ
2 28/B/F 10 MMF 2 gm/day, HCQ, Pred. 15 mg/day
3 38/B/F 10 MMF 2.5 gm/day, HCQ, Pred. 12 mg/day
4 25/W/F 7 Pred. 5 mg/day
5 23/W/M 5 HCQ, Pred. 5 mg/day
6 53/W/F 12 Pred. 60 mg/day
7 23/W/F 12 HCQ, Pred. 20 mg/day
8 30/W/F 8 MMF 2.5 gm/day, HCQ, Pred. 20 mg/day
9 31/W/F 6 MMF 2 gm/day, HCQ, quinacrine, Pred. 10 mg/day
10 24/W/F 8 MMF 2 gm/day, HCQ, Pred. 36 mg/day
11 41/W/F 10 Pred. 15 mg/day
12 54/W/F 2 HCQ
13 38/W/F 0 Pred. 1.5 mg/day
14 43/W/F 0 Pred. 5 mg/day, MTX, MMF
Control subjects
15 65/W/F Dermatomyositis Pred. 10 mg/day, MTX, MMF
16 39/W/F CNS vasculitis Pred. 15 mg/day, CYC
17 34/W/F WG Pred. 40 mg/day, CYC, etanercept
* SLEDAI  Systemic Lupus Erythematosus Disease Activity Index; HCQ  hydroxychloroquine; MMF  mycophenolate mofetil; Pred. 
prednisone; MTX  methotrexate; CNS  central nervous system; CYC  cyclophosphamide; WG  Wegener’s granulomatosis.
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confirmed using real-time RT-PCR to compare CD70
mRNA levels in untreated cells and cells treated with
5-azaC and the ERK pathway inhibitor U0126. U0126
inhibits DNA methylation by decreasing levels of DNA
methyltransferase 1 (Dnmt1) and Dnmt3a (18). Figure
1B shows that both drugs increased the expression of
CD70 mRNA relative to that of -actin.
Comparison of DNA methylation inhibitors on
CD70 expression. The effects of DNA methylation
inhibitors on T cell CD70 expression were further con-
firmed by treating T cells with a panel of DNA methyl-
ation inhibitors and measuring CD70 by flow cytometry.
The panel of inhibitors we used included 5-azaC, an
irreversible DNA methyltransferase inhibitor (24), pro-
cainamide, a competitive DNA methyltransferase inhib-
itor (17), and the ERK pathway inhibitors PD98059,
U0126, and hydralazine.
Kinetic analyses performed by flow cytometry on
days 1, 3, 5, and 7 after treatment with all 5 drugs
demonstrated that the increase in CD70 expression was
maximal at 3 days after treatment (data not shown).
Figure 2A shows representative histograms of the CD70
Figure 1. A, Effect of DNA methylation inhibition on CD70 expres-
sion. Phytohemagglutinin (PHA)–stimulated T cells were treated with
1 M 2-deoxy-5-azacytidine (5-azaC) for 3 days, and CD70 expression
was analyzed using oligonucleotide arrays. Results are expressed
relative to untreated cells. B, PHA-stimulated T cells were untreated
(medium alone) or were treated with 1 M 5-azaC, DMSO, or 40 M
U0126 dissolved in DMSO. Three days later, the cells were harvested,
and CD70 and -actin mRNA were measured by real-time reverse
transcription–polymerase chain reaction. Results are presented as the
ratio of CD70 to -actin. All values are the mean  SEM of 2
experiments.
Figure 2. Increased CD70 expression induced by DNA methylation inhibitors. Phytohemagglutinin-stimulated T cells from normal subjects were
treated with the indicated drugs, and 3 days later, treated and untreated cells were stained with fluorescein isothiocyanate (FITC)–labeled anti-CD70
and analyzed by flow cytometry. Solid histograms show CD70 expression on untreated T cells; open histograms show expression on T cells treated
with A, 5-azacytidine, C, procainamide, E, hydralazine, G, PD98059, and I, U0126. Dose-response curves show the ratio of the mean fluorescence
intensity (MFI) of T cells treated with B, 5-azacytidine (5-azaC), D, procainamide (Pca), F, hydralazine (Hyd), H, PD98059, and J, U0126 to the
MFI in the respective control groups. Values are the mean  SEM (n  5 experiments in B, H, and J; n  6 experiments in D and F). P values were
determined by analysis of variance.
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expression in untreated, PHA-stimulated T cells and in
T cells treated with 1 M 5-azaC for 3 days. A small
increase was seen. Figure 2B shows the effect of a range
of 5-azaC concentrations on CD70 expression, with 1
M producing the greatest effect (P  0.001 overall by
analysis of variance; n  5 experiments). The relatively
small magnitude of the change probably reflects the fact
that 5-azaC has significant toxicities (24). Figure 2C
shows histograms of CD70 expression on untreated T
cells and T cells treated with 20 M procainamide, and
Figure 2D shows an increase in the ratio of the mean
fluorescence intensity (MFI) of CD70 expression in
treated cells to that in untreated cells (P  0.032; n  6
experiments).
Similarly, Figure 2E shows the effect of 20 M
hydralazine on CD70 expression, and Figure 2F shows
the dose-response curve of 6 experiments. A significant
increase was seen (P  0.003). Figure 2G shows the
effect of 25 M PD98059 on CD70 expression, and 2H
shows the dose-response curve, demonstrating an in-
crease in CD70 MFI (P  0.012; n  5). Figure 2I shows
the effect of 40 M U0126 on CD70 expression, and
Figure 2J shows the dose-response curve, demonstrating
an increase (P  0.002; n  5). In this series of
experiments, there was no significant difference in the
maximum increase caused by the DNA methyltrans-
ferase inhibitor procainamide and the ERK pathway
inhibitors PD98059 and U0126.
Similar studies were performed examining the
effects of the DNA methylation inhibitors on CD70
expression in CD4 and CD8 T cell subsets. We found
that 1 M 5-azaC increased CD70 MFI on CD4 T cells
by 1.53  0.45–fold (P  0.025; n  5 experiments), 25
M PD98059 increased the MFI by 1.63  0.43–fold
(P  0.032; n  3), and 40 M U0126 increased the MFI
by 3.20  0.44–fold (P  0.039; n  4). In contrast to the
CD4 population, the increase in CD70 MFI was
smaller on CD8 T cells and did not reach statistical
significance for any of the drugs tested. However, this
smaller increase may account for the suggestion of 2
populations seen in T cells treated with U0126 (Figure
2I, where CD70 MFI increased 2.83  0.95–fold [P 
0.085]). This also most likely accounts for the greater
increase in expression observed on the CD4 popula-
tion relative to the polyclonal cells, particularly for the
cells treated with U0126.
It was possible that the drug treatments selected
for overgrowth or survival a T cell subset that overex-
pressed CD70. To exclude this possibility, the cloned
human tetanus toxoid–reactive T cell clone TT48E was
treated with 1 M 5-azaC and 40 M U0126 for 3 days
as above. In 6 serial experiments, CD70 expression
increased 1.69  0.33–fold (P  0.048) on the 5-azaC–
treated cells and 1.87  0.37–fold (P  0.004) on the
U0126-treated cells. This is evidence against subset
selection by the drug treatment. The smaller increase
observed in the U0126-treated cloned cells relative to
the uncloned cells may reflect differences between the
cloned line and primary polyclonal cells.
Effect of DNA methylation inhibitors on CD70-
dependent B cell help. Since CD70 participates in T
cell–dependent B cell stimulation (16), the effects of
DNA methylation inhibitors on CD70-dependent B cell
help were examined. Unfractionated T cells were stim-
ulated with PHA, treated with 5-azaC or U0126 as
above, and 3 days later, the treated cells were cultured
with PWM and varying numbers of autologous B cells,
with and without anti-CD70. Eight days later, total IgG
in the supernatants was measured by ELISA. Optimal
results were routinely observed at T cell to B cell ratios
of 1:4 (see below). B cells cultured with 5-azaC–treated
T cells and with U0126-treated T cells secreted greater
amounts of IgG than did B cells cultured with the same
numbers of untreated T cells (P  0.05) (Figure 3). This
finding is consistent with earlier reports that increasing
the CD70 expression by transfection increases B cell IgG
production in similar systems (16). Furthermore, the
Figure 3. Increased B cell costimulation by polyclonal T cells treated
with DNA methylation inhibitors, and reversal with anti-CD70.
Phytohemagglutinin-stimulated T cells were treated with 1 M
5-azacytidine (5-azaC) or 40 M U0126 for 3 days and then cocultured
with pokeweed mitogen and autologous B cells at a ratio of 1:4. Values
are the mean  SEM of 3 independent experiments.   P  0.05
versus cultures with and without anti-CD70.   P  0.05 versus
treated T cells. Controls included B cells cultured alone (IgG 10  5
g/ml), B cells plus lipopolysaccharide (LPS; IgG 136  9 g/ml), and
B cells plus LPS and anti-CD70 (IgG 125  8 g/ml).
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addition of anti-CD70 decreased IgG production by the
treated cells (P  0.05). A suppressive effect of anti-
CD70 on B cells was unlikely, because stimulating
purified B cells with lipopolysaccharide (LPS) then
adding the same amount of anti-CD70 yielded no signif-
icant inhibition of IgG synthesis (B cells plus LPS 136 
9 g/ml and B cells plus LPS and anti-CD70 125  8
g/ml).
These results were confirmed using the cloned,
CD4, tetanus toxoid–reactive human T cell line
TT48E. The T cells were again treated for 3 days with
5-azaC or U0126. To further exclude the possibility that
anti-CD70 interacted with CD70 on B cells, the T cells
were pretreated with anti-CD70 for 30 minutes at 4°C,
washed, and then cultured with autologous B cells. Since
our group has reported that T cells treated with DNA
methylation inhibitors also induce T cell autoreactivity
and that the autoreactive cells can directly stimulate B
cell IgG secretion (3), these studies were performed
without the addition of PWM. Figure 4 shows that the
cloned T cells treated with either 5-azaC or U0126
induced B cells to produce greater amounts of IgG than
did untreated T cells (P  0.05), similar to our previous
report. Furthermore, pretreatment of the T cells with
anti-CD70 decreased IgG synthesis, indicating a direct
effect on T cells.
Overexpression of CD70 on T cells from patients
with active lupus. T cells from patients with active lupus
have decreased levels of total genomic dmC (10), and the
same CD11a and perforin sequences demethylate in
lupus T cells as in T cells treated with 5-azaC (8,12). We
therefore sought to determine whether CD70 is also
overexpressed on lupus T cells. Figure 5A compares
representative histograms showing CD70 expression on
T cells from a patient with active lupus (SLEDAI score
12) and a matched control subject. Figure 5B shows
CD70 expression on PHA-stimulated normal T cells
with and without U0126 treatment. A similar pattern of
overexpression was seen in lupus T cells as in the
drug-treated T cells.
Figure 5C compares the percentage of peripheral
blood T lymphocytes expressing CD70 in 11 patients
with active lupus and 11 healthy controls. Significantly
more T cells from lupus patients expressed CD70 (P 
0.047). Figure 5D compares CD70 expression on CD4
and CD8 T cells from normal controls and lupus
patients. Significantly more CD4 T cells from the
lupus patients expressed CD70 than did those from the
controls (P  0.05), and relatively few CD8 T cells
expressed CD70.
Since T cell DNA methylation decreases in pro-
portion to lupus disease activity, we determined whether
disease activity affects T cell CD70 expression. To
minimize interexperimental variability, each lupus pa-
tient was paired with an age-, sex-, and race-matched
control subject for this analysis. The ratio of the CD70
MFI on T cells from lupus patients and controls was
determined and plotted against disease activity, as de-
termined by the SLEDAI (Figure 5E). The increase in
CD70 expression was directly related to disease activity
(P  0.036 by regression analysis). We similarly studied
3 patients with inactive lupus (SLEDAI score 2, 0, and 0,
respectively). The CD70 MFI ratio in patients and
controls was 0.94  0.05, indicating no overexpression in
patients with inactive disease.
Since CD70 is preferentially expressed on acti-
vated T cells (15) and since T cells from patients with
active lupus are frequently activated (25), we deter-
mined whether CD70 expression on T cells from patients
with active lupus reflected T cell activation. Purified T
cells from 4 patients with active lupus (patients 7, 8, 10,
and 11 in Table 1) and 4 control subjects were stained
with anti–HLA–DR and anti-CD70 and analyzed by flow
cytometry (Figure 5F). CD70 was preferentially ex-
pressed on HLA–DR–negative lupus patients’ T cells
(P  0.05). Using the data shown in Figure 5F, an
unpaired t-test, and alpha level of 0.05, as few as 2
Figure 4. Increased B cell costimulation by cloned T cells treated with
DNA methylation inhibitors, and reversal with anti-CD70. TT48E cells
were treated with 1 M 5-azacytidine (5-azaC) or 40 M U0126 for 3
days and then cocultured with autologous B cells at the indicated
ratios. T cells were pretreated with anti-CD70 where indicated. Values
are the mean  SEM of 4 independent experiments.   P  0.05
versus cultures with and without pretreatment of T cells with anti-
CD70.   P  0.05 versus untreated T cells. Controls consisted of B
cells cultured alone (IgG 7.5  5 g/ml), B cells plus lipopolysaccha-
ride (LPS; IgG 114  8 g/ml), and B cells plus LPS and anti-CD70
(IgG 112  8 g/ml).
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subjects per group would give 90% power to detect a
difference in CD70 expression on HLA–DR–negative T
cells. The CD70 overexpression on T cells lacking acti-
vation markers is similar to the overexpression of LFA-1
and perforin on T cells (8) and suggests that mechanisms
other than T cell activation likely contribute to CD70
overexpression.
We considered the possibility that higher immu-
nosuppression might contribute to this finding. How-
ever, the patients were taking different combinations of
immunosuppressive agents, which does not support this
possibility. Still, many of the patients were receiving
prednisone. We therefore studied CD70 expression on
CD4 T cells from 3 patients receiving prednisone and
various cytotoxic agents but with autoimmune diseases
other than lupus (Table 1) and 3 matched healthy
controls. No increase in CD70 was seen (0.59  0.29%
CD4,CD70 cells in patients versus 0.65  0.51% in
controls). To further exclude this possibility, PBMCs
were stimulated with PHA, then stimulated and un-
stimulated cells were cultured for 24 hours in the
presence or absence of graded concentrations (1–100
M) of medications representative of the classes com-
monly used to treat lupus and not requiring metabolism
for activation. These included indomethacin (for non-
steroidal antiinflammatory drugs), chloroquine (for an-
timalarials), hydrocortisone (for steroids), and 6-MP
(for azathioprine). CD70 and CD4 expression were then
measured by flow cytometry. No increase in CD70
expression was seen on stimulated or unstimulated
Figure 5. Overexpression of CD70 on T cells from patients with systemic
lupus erythematosus (SLE). A, T cells were isolated from a patient with
active SLE (SLE Disease Activity Index [SLEDAI] score 12) or a
matched control subject (C), and CD70 expression was compared by flow
cytometry. B, T cells from a healthy control subject were stimulated with
phytohemagglutinin, treated with 40 M U0126 as described in Figure 2,
and CD70 expression was compared with that in untreated (control [C])
cells as in A. C, Percentage of CD70 T cells isolated from the peripheral
blood of 11 patients with active SLE (SLEDAI score 5) and 11 healthy
controls. Values are the mean  SEM of 11 experiments. D, Purified T
cells from 4 patients with active SLE and 4 age- and sex-matched controls
were stained for CD70, CD4, and CD8 expression, as indicated. Values
are the mean  SEM of 4 experiments.   P  0.05 versus control and
versus CD70,CD8 cells. E, Ratio of the mean fluorescence intensity
(MFI) of CD70 expression by T cells from 11 patients with active SLE to
the MFI of CD70 expression by T cells from age- and sex-matched
controls are plotted against the SLEDAI score of the SLE patients. F,
Purified T cells from the peripheral blood of 4 controls and 4 SLE patients
were stained with anti-CD70 and anti–HLA–DR and then analyzed by
flow cytometry. Values are the mean  SEM of the 4 experiments.
Figure 6. Anti-CD70 inhibition of IgG synthesis induced by lupus T
cells. T cells from controls and patients with active lupus were cultured
with autologous B cells at the indicated ratios for 8 days. Where
indicated, the T cells were pretreated with anti-CD70 antibody (Ab).
IgG was measured by enzyme-linked immunosorbent assay as de-
scribed in Figure 3. Values are the mean  SEM of 3 independent
experiments.   P  0.05 versus controls and versus anti-CD70
pretreatment. Controls included B cells cultured alone (IgG 37  5
g/ml), B cells plus lipopolysaccharide (LPS; IgG 2,410  80 g/ml),
and B cells plus LPS and anti-CD70 (IgG 2,330  90 g/ml).
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CD4 cells. Thus, other mechanisms, such as DNA
hypomethylation, could play a role.
Contribution of CD70 to B cell activation by
lupus T cells. To determine if CD70 overexpression on
lupus T cells could contribute to B cell activation similar
to T cells demethylated with 5-azaC or U0126, T cells
from 3 patients with active lupus and 3 healthy controls
were treated with anti-CD70 for 30 minutes at 4°C as
above, then cultured for 8 days with purified autologous
B cells at varying T cell to B cell ratios without PWM.
Figure 6 shows that at all ratios tested, lupus T cells
stimulated IgG synthesis significantly better (P  0.05)
than controls and that a T cell:B cell ratio of 1:4 resulted
in optimal B cell activation. Using the results shown for
a T cell:B cell ratio of 1:4, an unpaired t-test, and alpha
level of 0.05, there was 94% power to detect a difference
between the lupus patients and controls with 3 subjects
per group. Furthermore, anti-CD70 significantly de-
creased (P  0.05) IgG production to levels that were
not significantly different from those in controls at all
cell ratios tested, similar to the results in experimentally
hypomethylated T cells (Figures 3 and 4).
DISCUSSION
The novel findings reported in this paper include
the following. CD70 is overexpressed on polyclonal, as
well as cloned, CD4 T cells treated with a panel of
DNA methylation inhibitors. CD70-overexpressing poly-
clonal and cloned CD4 T cells overstimulate B cell IgG
production, and the stimulation can be inhibited with
anti-CD70. CD70 is overexpressed on CD4 T cells
from patients with SLE. Anti-CD70 inhibits the abnor-
mal T cell–dependent IgG secretion that characterizes
lupus B cells (26).
The initial oligonucleotide array studies as well as
earlier work by our group and others have identified
100 T cell genes which reproducibly increase expres-
sion following treatment with 5-azaC. These include
CD11a (11), interferon- (27), IL-6 (4), IL-4 (27),
perforin (9), and now CD70. We selected CD70 for
further study because of its potential for contributing to
B cell activation. CD70 is expressed on activated T cells
and B cells (15) and is expressed on 5–15% of the T cells
in the peripheral blood of healthy individuals; these bear
the activation marker HLA–DR (28). CD70 binds CD27
and provides costimulatory signals for B cell IgG pro-
duction (16). B cells in the peripheral blood of patients
with active lupus are abnormally activated and secrete
polyclonal IgG, and this is a T cell–dependent process
(26). We therefore hypothesized that CD70 might play a
role in this abnormal B cell activation.
The array studies were confirmed by demonstrat-
ing that PHA-stimulated T cells treated with the irre-
versible DNA methyltransferase inhibitor 5-azaC or the
MEK inhibitor U0126 also increased CD70 expression
at both the mRNA and protein levels, consistent with an
effect on DNA methylation. Increases at the protein
level were further confirmed using procainamide and 2
additional ERK pathway inhibitors, PD98059 and hy-
dralazine. Inhibiting ERK pathway signaling decreases
the DNA methyltransferases Dnmt1 and Dnmt3a in
stimulated T cells, which leads to DNA hypomethylation
(18,19,29). Importantly, ERK pathway signaling and
DNA methyltransferase expression are decreased in
lupus T cells, suggesting that inhibiting DNA methyl-
ation with ERK pathway inhibitors may be relevant to
idiopathic lupus (19). Similarly, since the lupus-inducing
drugs procainamide and hydralazine both increased
CD70 expression, the observations reported here may be
relevant to drug-induced lupus syndromes as well. The
effects of these drugs were greater on CD4 T cells than
on CD8 T cells, although a small increase was detected
in the CD8 subset, which approached, but did not
achieve, statistical significance, particularly with U0126.
The reason for the differential effect is unknown. How-
ever, differential effects of 5-azaC on perforin expres-
sion have been observed in CD4 and CD8 T cells,
reflecting differences in the methylation status of an
upstream enhancer between the subsets (9). A similar
mechanism could contribute to the differential effect in
the CD70 response to 5-azaC in CD4 and CD8 cells.
While we have reported that the panel of drugs
used in the present studies can inhibit T cell DNA
methylation (2,18), the present studies did not identify
the demethylated sequences that affect CD70 expres-
sion. In other studies, our group has used bisulfite
sequencing and regional methylation of reporter con-
structs to characterize how DNA methylation inhibitors
and lupus increase CD11a and perforin expression. We
found that demethylation of sequences flanking the
CD11a promoter increase CD11a expression in vitro and
in lupus (12). Similarly, demethylation of a region
linking an enhancer and minimal promoter, located
600–800 bp 5 of the perforin transcription start site, is
responsible for the increase in perforin in vitro and in
lupus, although methylation changes also occur else-
where but are transcriptionally irrelevant (8,9). In more
preliminary work, we have found that the 5 DNA-
hypomethylating drugs used in these studies demethyl-
ate a region 500 bp 5 of the CD70 transcription start
site, and that the same region is hypomethylated in
CD4 T cells from patients with active lupus (Oelke K,
et al: unpublished results). Whether these methylation
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changes modify CD70 transcription, and whether the
methylation is the same in CD4 and CD8 T cells, is
currently unknown. Studies characterizing the CD70
promoter and the effects of methylation on its function
are currently in progress.
Since other investigators have reported that cells
transfected with CD70 will enhance PWM-induced IgG
secretion, a T cell–dependent response (16), we wanted
to determine whether T cells overexpressing CD70 may
have similar effects on B cells. The initial studies com-
pared untreated polyclonal T cells with the same cells
treated with a DNA methyltransferase inhibitor and a
MEK inhibitor. The drug-treated cells enhanced PWM-
induced IgG secretion, and the effect was reversed with
anti-CD70, which supports the hypothesis that T cell
CD70 overexpression may contribute to the increase in
IgG synthesis. The possibility that the effects might have
been indirect due to effects of the drugs on a T cell
subset lacking CD70, but requiring CD70 cells, is
unlikely because cloned T cells gave similar results. The
possibility that anti-CD70 delivered a suppressive signal
through B cell CD70 was tested by pretreating the T cell
clones with anti-CD70 before adding them to the B cells,
and we demonstrated suppression of the IgG response.
Controls using LPS and purified B cells also indicated
that anti-CD70 does not have a direct suppressive effect
on B cells. Thus, these results, together with the earlier
reports that cells transfected with CD70 overstimulate B
cells, support the contention that CD70 on T cells
contributes to the increased B cell IgG production.
Flow cytometry studies examining CD70 expres-
sion on T cells from patients with active lupus and age-,
race-, and sex-matched healthy controls demonstrated
that CD70 was overexpressed on CD4 T cells from the
lupus patients and that the degree of overexpression was
directly proportional to disease activity. This is similar to
the expression of CD11a and perforin, two other
methylation-sensitive genes, and may reflect the DNA
hypomethylation that characterizes T cells from patients
with active disease. Again, the observation that T cells
treated with DNA methylation inhibitors caused a lupus-
like disease suggests that the DNA hypomethylation may
induce the autoimmune disease, rather than reflect an
effect secondary to the disease process. Since CD70 is
expressed on stimulated T cells (15), it was possible that
the increased expression was due to in vivo T cell
activation. However, while CD70 is expressed on acti-
vated T cells in healthy individuals (30), CD4 T cells
overexpressing CD70 were largely HLA–DR–negative.
There also appeared to be no correlation with medica-
tions. This suggests that the overexpression is due to
other processes, such as DNA hypomethylation.
The role of CD70 in the abnormal B cell activa-
tion that characterizes lupus (26) was then examined. B
cells in the peripheral blood of patients with active lupus
are abnormally activated and secrete polyclonal IgG.
While some of the antibodies secreted are the autoan-
tibodies usually associated with SLE (26), other B cells
secrete antibodies to antigens present on sheep erythro-
cytes and even keyhole limpet hemocyanin (31), suggest-
ing that there is nonspecific polyclonal activation. Other
investigators have reported that anti–IL-6 or anti–IL-6
receptor will inhibit this abnormal activation (32,33), but
the mechanisms causing the IL-6 secretion have been
unexplored. T cells from patients with active lupus
stimulated IgG synthesis by autologous B cells in the
absence of added antigen or mitogen, as reported by
others (34). Pretreatment of the T cells with anti-CD70
abrogated this response. These studies thus suggest that
T cell CD70 is required for the abnormal B cell stimu-
lation in lupus. The present studies also suggest that
CD70 overexpression on lupus T cells might contribute
to B cell stimulation, together with other molecules,
such as CD40L (35), and that inhibiting any of the
costimulatory molecules is sufficient to decrease the
antibody response to normal levels. Furthermore, IL-10,
which is elevated in the serum of patients with SLE (36),
is synergistic with the effects of CD27–CD70 interac-
tions, which may lead to further increases in immuno-
globulin synthesis (37).
Finally, the studies described above extend pre-
vious studies by our group examining mechanisms by
which experimentally hypomethylated CD4 T cells
cause autoimmunity in animal models and determining
whether the same mechanisms could contribute to idio-
pathic human lupus. In earlier work, we demonstrated
that LFA-1 overexpression contributes to the auto-
immune disease induced by T cells that had been
experimentally demethylated with 5-azaC, procain-
amide, hydralazine, and U0126 (5,7,18) and that T cells
from patients with active lupus overexpress LFA-1
(11,12). Comparing the magnitude of the effect of these
drugs on CD70 and LFA-1 is difficult, because LFA-1 is
a 2-chain molecule and 5-azaC only affects CD11a (11),
so the increase is limited by the amount of CD18
available. More recently, we reported that perforin
expression is also abnormally increased in CD4 T cells
treated with DNA methylation inhibitors (9) and in
CD4 T cells from patients with active lupus, and it may
contribute to disease pathogenesis by participating in
autologous macrophage killing (8,9,14). The magnitude
1858 OELKE ET AL
of the effect of 5-azaC on CD70 and perforin expression
in CD4 T cells is comparable (9). We report here that
CD70 is also overexpressed in both experimentally hy-
pomethylated CD4 T cells and in CD4 lupus T cells
and may contribute to disease pathogenesis by augment-
ing B cell stimulation. Thus, DNA hypomethylation may
contribute to lupus pathogenesis through effects on
multiple genes that participate in multiple disease-
augmenting mechanisms.
These observations also raise the possibility that
administration of procainamide or hydralazine to pa-
tients with active lupus might worsen their disease.
However, since these drugs only affect DNA methyl-
ation in the S phase (38) and since T cells from patients
with active lupus are typically anergic (39), this question
is difficult to address in vitro. Nonetheless, these results
raise the possibility that the strategy of identifying
methylation-sensitive T cell genes in experimentally
hypomethylated T cells may predict genes that are
abnormally expressed in lupus T cells and contribute to
the disease process.
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